This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This will be a single centre, randomised, double-blind, placebo-controlled, 2-period
crossover study to investigate the effect of treatment with repeat inhaled doses of GSK256066
on bronchial hyper-reactivity to adenosine monophosphate.